Nectar Lifesci.

When is the next results date for Nectar Lifesci.?

No Upcoming Board Meetings

What does Nectar Lifesci. do?

Nectar Lifescience Ltd is a pharmaceutical company focused on manufacturing high-quality products, particularly in the Cephalosporins segment. As of December 2024, it reported net sales of 455 Cr and a net profit of 8 Cr, with a market cap of Rs 544 Cr.

Overview: <BR>Nectar Lifescience Ltd is an integrated pharmaceutical organization specializing in the manufacturing and delivery of high-quality pharmaceutical products, particularly in the Cephalosporins segment, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>History: <BR>Nectar Lifescience Limited was incorporated on June 27, 1995, originally named 'Surya Medicare Limited'. The company changed its name to 'Nectar Lifescience Limited' on March 26, 2004. The latest quarterly results reported net sales and net profit for December 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 455 Cr (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: 8 Cr (Quarterly Results - Dec 2024) <BR>Market-cap value: Rs 544 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.57 <BR>Return on Equity: 1.00% <BR>Price to Book: 0.51 <BR><BR>Contact Details: <BR>Address: Village Saidpura, Tehsil Derabassi S A S Nagar Mohali Punjab : 140507 <BR>Tel: 91-1762-308000 <BR>Email: cs@neclife.com <BR>Website: http://www.neclife.com

Who are in the management team of Nectar Lifesci.?

As of March 2022, the management team of Nectar Lifesci includes Sanjiv Goyal (Chairman & Managing Director), Ajay Swaroop, Rupinder Tewari, Kuldip Kumar Bhasin, Indu Pal Kaur (all Independent Directors), Meena Verma (Nominee), Anubha (Company Secretary & Compliance Officer), and Puneet Sud (Director of Operations). The team consists of a mix of executive and independent directors.

As of March 2022, the management team of Nectar Lifesci includes the following individuals:<BR><BR>1. Sanjiv Goyal - Chairman & Managing Director<BR>2. Ajay Swaroop - Independent Director<BR>3. Meena Verma - Nominee<BR>4. Rupinder Tewari - Independent Director<BR>5. Anubha - Company Secretary & Compliance Officer<BR>6. Kuldip Kumar Bhasin - Independent Director<BR>7. Indu Pal Kaur - Independent Director<BR>8. Puneet Sud - Director (Operation)<BR><BR>This team comprises a mix of executive and independent directors, along with a company secretary responsible for compliance.

Has Nectar Lifesci. declared dividend?

Nectar Lifescience Ltd has declared a 5% dividend, amounting to 0.05 per share, with an ex-date of September 11, 2020. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different periods.

Nectar Lifescience Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.05<BR>- Ex-date: 11 Sep 20<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -26.58%, the dividend return was 0%, resulting in a total return of -26.58%.<BR><BR>For the 1-year period, the price return was -20.92%, the dividend return was 0%, leading to a total return of -20.92%.<BR><BR>Over the 2-year period, the price return was 40.37%, the dividend return was 0%, which resulted in a total return of 40.37%.<BR><BR>In the 3-year period, the price return was -3.98%, the dividend return was 0%, culminating in a total return of -3.98%.<BR><BR>During the 4-year period, the price return was -27.77%, the dividend return was 0%, resulting in a total return of -27.77%.<BR><BR>For the 5-year period, the price return was 67.52%, the dividend return was 0.21%, leading to a total return of 67.73%.<BR><BR>Overall, while Nectar Lifescience Ltd declared a dividend, the dividend yield remains at 0%. The total returns show significant variability, with a notable positive return over the 2-year and 5-year periods, contrasting with negative returns in shorter time frames.

Who are the peers of the Nectar Lifesci.?

Nectar Lifesci. has peers including Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma, Medicamen Biotec, and Kerala Ayurveda. It exhibits below average management risk and capital structure, with a 1-year return of -23.21%, the lowest among its peers.

Peers: Nectar Lifesci. has the following peers: Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma., Medicamen Biotec, and Kerala Ayurveda.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Venus Remedies, Shukra Pharma., and Medicamen Biotec. Below Average management risk is noted for Nectar Lifesci., Kerala Ayurveda, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Nectar Lifesci., Medicamen Biotec, Kerala Ayurveda, and the rest. Average growth is reported for Venus Remedies and Shukra Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and Medicamen Biotec, while Good capital structure is noted for Torrent Pharma and Shukra Pharma. Below Average capital structure is observed at Nectar Lifesci., Kerala Ayurveda, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Nectar Lifesci. has the lowest at -23.21%. Nectar Lifesci.'s 1-year return is significantly lower than the highest peer. Additionally, the six-month return is negative for Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Medicamen Biotec, and Nectar Lifesci.

Is Nectar Lifesci. technically bullish or bearish?

As of July 7, 2025, the market trend is mildly bearish, influenced by bearish daily moving averages and weekly Bollinger Bands, despite some mildly bullish signals from the MACD and KST, indicating a cautious outlook.

As of 7 July 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating bearishness and the weekly Bollinger Bands also showing a mildly bearish signal. The MACD on the weekly timeframe is mildly bullish, which provides some counterbalance, but the overall indicators suggest a lack of strong bullish momentum. The KST is mildly bullish on the weekly but remains bearish on the monthly, further indicating mixed signals. The lack of clear trends in Dow Theory and the OBV being mildly bearish on the monthly reinforce the cautious outlook.

Is Nectar Lifesci. overvalued or undervalued?

As of July 8, 2025, Nectar Lifesciences is considered overvalued and risky due to its negative PE ratio of -3.66 and poor financial metrics compared to peers, alongside a significant year-to-date stock underperformance of -52.49% against the Sensex's 7.13% return.

As of 8 July 2025, Nectar Lifesciences has moved from an attractive to a risky valuation grade. The company appears to be overvalued given its negative PE ratio of -3.66, an EV to EBIT of -11.55, and an EV to EBITDA of -38.76. These figures indicate significant financial distress compared to its peers, such as Sun Pharma, which has a PE ratio of 35.1 and an EV to EBITDA of 24.8, and Cipla, with a PE of 22.8 and an EV to EBITDA of 15.79.<BR><BR>The stark contrast in valuation metrics highlights Nectar Lifesciences' precarious position within the pharmaceuticals and biotechnology industry. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -52.49% compared to the Sensex's 7.13%. This further reinforces the conclusion that Nectar Lifesciences is overvalued in its current state.

Who are the top shareholders of the Nectar Lifesci.?

The top shareholders of Nectar Lifesci include individual investors holding approximately 44.12%, with Sanjiv Goyal as the largest promoter at 24.9%. Notably, 99.6% of promoter holdings are pledged, and the highest public shareholder is Jaideep Sampat at 2%.

The top shareholders of Nectar Lifesci include a mix of individual and institutional investors. The majority of the shares are held by non-institutional shareholders, with individual investors holding approximately 44.12% of the company. The promoter with the highest holding is Sanjiv Goyal, who owns 24.9% of the shares. Additionally, there are 17 foreign institutional investors (FIIs) holding about 0.81% of the company. The highest public shareholder is Jaideep Sampat, with a holding of 2%. It's worth noting that a significant portion of the promoter holdings, about 99.5995%, is pledged.

How big is Nectar Lifesci.?

As of 24th July, Nectar Lifescience Ltd has a market capitalization of 396.00 Cr and reported net sales of 1673.07 Cr with a loss of 113.68 Cr over the latest four quarters. Shareholder's funds were 1,069.25 Cr and total assets were 2,183.58 Cr as of March 2024.

As of 24th July, Nectar Lifescience Ltd has a market capitalization of 396.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 1673.07 Cr. However, it experienced a loss of 113.68 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 1,069.25 Cr and total assets were reported at 2,183.58 Cr.

How has been the historical performance of Nectar Lifesci.?

Nectar Lifesci has experienced significant financial declines, with net sales dropping from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025, and operating profit turning negative with a loss of 26.46 Cr in March 2025. Key metrics, including profit before tax and profit after tax, have also deteriorated, reflecting an overall downward trend in performance.

Answer:<BR>The historical performance of Nectar Lifesci shows significant fluctuations in financial metrics over the years.<BR><BR>Breakdown:<BR>Nectar Lifesci's net sales peaked at 2,782.94 Cr in March 2019 but have since declined, reaching 1,673.07 Cr in March 2025. The total operating income followed a similar trend, decreasing from 2,782.94 Cr in March 2019 to 1,673.07 Cr in March 2025. The company experienced a notable drop in operating profit, with a loss of 26.46 Cr in March 2025 compared to a profit of 166.14 Cr in March 2024. This decline in profitability is reflected in the profit before tax, which fell to -161.53 Cr in March 2025 from a profit of 18.27 Cr in the previous year. The profit after tax also turned negative, resulting in a loss of 113.68 Cr in March 2025, contrasting with a small profit of 4.99 Cr in March 2024. The company's total liabilities decreased from 2,183.58 Cr in March 2024 to 1,992.18 Cr in March 2025, while total assets also declined from 2,183.58 Cr to 1,992.18 Cr in the same period. Cash flow from operating activities was 169 Cr in March 2025, down from 224 Cr in March 2024, indicating a decrease in operational efficiency. Overall, Nectar Lifesci's financial performance has shown a downward trend in key metrics over the past several years.

Are Nectar Lifescience Ltd latest results good or bad?

Nectar Lifescience Ltd's latest results are concerning, showing a Q3 FY26 net loss of ₹176.01 crores, a year-on-year decline of over 3,143%, and net sales of only ₹5.71 crores. The company's negative operating margin and return on equity indicate significant operational struggles, raising serious concerns about its future viability.

Nectar Lifescience Ltd's latest results indicate a troubling situation for the company. In Q3 FY26, the company reported a consolidated net loss of ₹176.01 crores, which represents a staggering decline of over 3,143% year-on-year. This significant loss is accompanied by net sales of just ₹5.71 crores, a slight decrease of 0.52% compared to the previous year, but a dramatic drop from ₹430.70 crores in Q4 FY25.<BR><BR>The operating margin remains deeply negative at -6.60%, reflecting the company's ongoing struggle to cover its operational expenses. Additionally, the return on equity (ROE) is at a concerning -17.19%, indicating severe capital inefficiency.<BR><BR>Overall, the financial performance of Nectar Lifescience is characterized by operational distress, with severe revenue contraction and mounting losses raising serious concerns about its viability and future prospects in the competitive pharmaceutical market. The company's situation is critical, and it is advisable for investors to approach with caution.

Should I buy, sell or hold Nectar Lifescience Ltd?

Why is Nectar Lifescience Ltd falling/rising?

As of 05-May, Nectar Lifescience Ltd's stock price is rising to 12.28, reflecting a 0.74% increase after a trend reversal. However, it has significant long-term declines, with a year-to-date drop of 37.03%, and mixed signals regarding short-term momentum due to decreased investor participation.

As of 05-May, Nectar Lifescience Ltd's stock price is rising, currently at 12.28, reflecting a change of 0.09 or 0.74% increase. This upward movement follows a trend reversal after two consecutive days of decline. The stock's performance today is reported to be inline with its sector, indicating that it is not an outlier in the market. <BR><BR>Despite the recent rise, the stock has experienced significant declines over longer periods, with a year-to-date drop of 37.03% and a one-year decline of 44.28%. However, it has shown a strong monthly performance, gaining 22.80% in the last month, which contrasts with the Sensex's increase of only 5.04% during the same period. <BR><BR>The stock's moving averages indicate that it is currently higher than the 20-day and 50-day moving averages, but lower than the 5-day, 100-day, and 200-day moving averages, suggesting mixed signals regarding its short-term momentum. Additionally, there has been a decrease in investor participation, with delivery volume falling by 2.8% against the 5-day average, which could indicate a lack of strong buying interest despite the recent price increase. <BR><BR>Overall, while the stock is currently rising, it is essential to consider the broader context of its recent performance and investor behavior.

Which are the latest news on Nectar Lifesci.?